| 货号 | 规格 | 价格 | 上海 | 北京 | 珠海 | 重庆 | 武汉 | 购买数量 |
|---|---|---|---|---|---|---|---|---|
S83125-1mg促销 |
≥98% | ￥682.00 ￥540.00 |
10 | - | - | - | - |
|
S83125-5mg促销 |
≥98% | ￥2060.00 ￥1650.00 |
10 | - | - | - | - |
|
S83125-10mg促销 |
≥98% | ￥3160.00 ￥2530.00 |
10 | - | - | - | - |
|
S83125-25mg促销 |
≥98% | ￥3750.00 ￥2990.00 |
10 | - | - | - | - |
|
S83125-50mg促销 |
≥98% | ￥5990.00 ￥4790.00 |
3 | - | - | - | - |
|
S83125-100mg促销 |
≥98% | ￥9590.00 ￥7670.00 |
3 | - | - | - | - |
|
| 产品描述： | TUG-770 is a potent, selective and orally active GPR40/FFA1 agonist with an EC50 of 6 nM for human FFA1. TUG-770 shows a high selectivity for FFA1 over FFA2, FFA3, FFA4, PPARγ, other receptors, transporters, and enzymes. TUG-770 can be uesd for type 2 diabetes research | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 靶点： | EC50: 6 nM (Human GPR40/FFA1);GPR | ||||||||||||||||||||
| 体内研究： | TUG-770 (Compound 22; 20 mg/kg; oral administration; daily; for 28 days) treatment significantly improves glucose tolerance, and has no effect on food intake, body weight, body composition or plasma leptin concentration. TUG-770 also significantly improves the insulin sensitivity index (plasma glucose x plasma insulin) | ||||||||||||||||||||
| 参考文献： | 1. Christiansen E, et al. Discovery of TUG-770: A Highly Potent Free Fatty Acid Receptor 1 (FFA1/GPR40) Agonist for Treatment of Type 2 Diabetes. ACS Med Chem Lett. 2013 May 9;4(5):441-445. | ||||||||||||||||||||
| 溶解性： | Soluble in DMSO | ||||||||||||||||||||
| 保存条件： | -20℃ | ||||||||||||||||||||
| 配置溶液浓度参考： |
|
||||||||||||||||||||
| 注意： | 部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，仅供客户参考交流研究之用。 |
上海工商
沪公网安备 31011702002021号
危险品化学品经营许可证（不带存储）
营业执照(三证合一)
